# Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

> **NCT02558387** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

## Interventions

- **DRUG:** BIBF1120

## Key facts

- **NCT ID:** NCT02558387
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2016-07
- **Final completion:** 2017-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02558387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02558387, "Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02558387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*